COPD has traditionally been treated as a homogenous disease, despite significant differences in its underlying causes, making it difficult to develop effective and personalized treatment options. This “one-size-fits-all” approach has contributed to the lack of success in clinical trials and recruitment of the “right” patients remains a great obstacle.
Recent positive clinical trials enrolling a distinct subset of patients highlight the need to identify clinically actionable COPD endotypes to promote successful treatment options. To address these challenges, we aim to leverage large volumes of biomarker data, multi-omics data, and clinical characteristics to investigate possible pathobiological drivers in COPD.
Together with our future partner, we will focus on using data-driven approaches to identify treatable endotypes, which have the potential of improving the efficacy of clinical trial recruitment and aid in the discovery of targeted treatment targets. We believe that this project represents an essential step towards a more personalized and effective approach to treating COPD. By utilizing Nordic Bioscience’s inflammation- and extracellular matrix-based biomarkers, we have a unique tool to evaluate the (end products of) causal molecular pathways leading to lung tissue destruction.
